Liz Hurlburt
Executive Vice President and Chief Clinical Strategy and Operations Officer
Replay available
CorMedix Inc. (NASDAQ: CRMD) Q1 2025 earnings conference call, held 2025-05-06. Replay captured from the company's public earnings webcast.

Executive Vice President and Chief Clinical Strategy and Operations Officer
Analyst, Learing Partners
Executive Vice President and CFO
LifeSci Advisors
Chief Executive Officer
Analyst, RBC Capital
Analyst, Truist Securities
Analyst, Needham and Company
Good day and welcome to the Corematics Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Dan Ferry, LifeSci Advisors. Please go ahead. Good morning, and welcome to the Corps of Medics first quarter 2025 earnings conference call. Leading the call today is Joe Tedisco, Chief Executive Officer of Corps of Medics. He is joined by Dr. Matt David, Executive Vice President and CFO. That's Zelnick Kaufman, EVP and Chief Legal and Compliance Officer, Liz Hurlburt, EVP and Chief Clinical Strategy and Operations Officer, and Aaron Mistry, EVP and Chief Commercial Officer. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial positions. Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CoreMedix's findings with the SEC, which are available free of charge at the SEC's website or upon request from CoreMedix. CoreMedix ma...